Payment overview · 2025
General Payments
$6,238.14
150 reported records · 22 companies
Healthcare provider profile · identity verified
Matthew Joseph Comstock, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · TULSA, OK · NPI 1174750749
Verified facts
What the public records show
CMS Open Payments records show Matthew Joseph Comstock, D.O. received $6,238.14 in general payments during 2025 across 150 reported records.
Cardio Flow, Inc. accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 52 associated products.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Cardio Flow, Inc. | Unresolved — no canonical attribution shown | $1,224.65 | 19.6% | 1 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $755.49 | 12.1% | 14 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $615.84 | 9.9% | 16 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $605.61 | 9.7% | 22 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $588.75 | 9.4% | 13 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $406.88 | 6.5% | 20 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $406.69 | 6.5% | 13 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $311.07 | 5.0% | 9 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$271.97 | 4.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $177.67 | 2.9% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $164.86 | 2.6% | 10 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $148.21 | 2.4% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $147.87 | 2.4% | 1 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $92.93 | 1.5% | 4 | 2025 |
| Medline Industries LP | Unresolved — no canonical attribution shown | $67.88 | 1.1% | 3 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $67.45 | 1.1% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $51.03 | 0.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.27 | 0.7% | 2 | 2025 |
| CathWorks, Inc. | Unresolved — no canonical attribution shown | $27.31 | 0.4% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $23.31 | 0.4% | 1 | 2025 |
| Cagent Vascular INC | Unresolved — no canonical attribution shown | $19.91 | 0.3% | 1 | 2025 |
| CashFlow Solutions, LLC | Unresolved — no canonical attribution shown | $16.49 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,486.52 | 148 |
| Acquisitions | $1,224.65 | 1 |
| Travel and Lodging | $526.97 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $535.00 | 13 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $447.36 | 15 | 2025 |
Source payment records
|
|||||
| IV Other Normalized: iv other |
Device | Philips North America LLC | $204.41 | 8 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $201.21 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $177.67 | 8 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $149.45 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $147.87 | 1 | 2025 |
Source payment records
|
|||||
| TURBOHAWK Normalized: turbohawk |
Device | Medtronic, Inc. | $122.52 | 1 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $103.47 | 3 | 2025 |
Source payment records
|
|||||
| RADIAL 360 Normalized: radial 360 |
Device | CORDIS US CORP. | $94.01 | 5 | 2025 |
Source payment records
|
|||||
| Pounce Venous Thrombectomy System Normalized: pounce venous thrombectomy system |
Device | Surmodics, Inc. | $92.93 | 4 | 2025 |
Source payment records
|
|||||
| Venovo Normalized: venovo |
Device | Bard Peripheral Vascular, Inc. | $71.84 | 4 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $67.45 | 5 | 2025 |
Source payment records
|
|||||
| VENACURE 1470 PRO Normalized: venacure 1470 pro |
Device | AngioDynamics, Inc. | $60.24 | 2 | 2025 |
Source payment records
|
|||||
| Specialty Tempus IC Monitor Normalized: specialty tempus ic monitor |
Device | Philips North America LLC | $56.88 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $51.03 | 2 | 2025 |
Source payment records
|
|||||
| SUPERA Normalized: supera |
Device | Abbott Laboratories | $47.86 | 3 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $42.53 | 2 | 2025 |
Source payment records
|
|||||
| PRECISE PRO RX Normalized: precise pro rx |
Device | CORDIS US CORP. | $42.03 | 3 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $39.26 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy System Normalized: pounce thrombectomy system |
Device | Surmodics, Inc. | $39.26 | 2 | 2025 |
Source payment records
|
|||||
| Sublime 014 Rx PTA Balloon Dilatation Catheter Normalized: sublime 014 rx pta balloon dilatation catheter |
Device | Surmodics, Inc. | $39.26 | 2 | 2025 |
Source payment records
|
|||||
| Sublime Microcatheter, 018, 200cm, Straight Normalized: sublime microcatheter 018 200cm straight |
Device | Surmodics, Inc. | $39.26 | 2 | 2025 |
Source payment records
|
|||||
| Encore Normalized: encore |
Device | Philips North America LLC | $34.56 | 2 | 2025 |
Source payment records
|
|||||
| Other Rental Normalized: other rental |
Device | Philips North America LLC | $34.43 | 2 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $30.81 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.84 | 1 | 2025 |
Source payment records
|
|||||
| HT Bilevel Pro Core Normalized: ht bilevel pro core |
Device | Philips North America LLC | $27.53 | 2 | 2025 |
Source payment records
|
|||||
| FFRANGIO Normalized: ffrangio |
Device | CathWorks, Inc. | $27.31 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| Laser Parts Other Normalized: laser parts other |
Device | Philips North America LLC | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.69 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| SABER Normalized: saber |
Device | CORDIS US CORP. | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| Serrantor Normalized: serrantor |
Device | Cagent Vascular INC | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| LUTONIX Drug Coated Balloon Normalized: lutonix drug coated balloon |
Device | Bard Peripheral Vascular, Inc. | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $19.04 | 2 | 2025 |
Source payment records
|
|||||
| General - CRM_CRM Normalized: general crm crm |
Device | Boston Scientific Corporation | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| LifeStream Normalized: lifestream |
Device | Bard Peripheral Vascular, Inc. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| LYMPHA PRESS OPTIMAL PLUS(US) BT Normalized: lympha press optimal plus us bt |
Device | CashFlow Solutions, LLC | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| PCD-51 731A (US) - White Normalized: pcd 51 731a us white |
Device | CashFlow Solutions, LLC | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| PCD-52 737A (US) White Normalized: pcd 52 737a us white |
Device | CashFlow Solutions, LLC | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| HI-TORQUE COMMAND Normalized: hi torque command |
Device | Abbott Laboratories | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| MYNXGRIP Normalized: mynxgrip |
Device | CORDIS US CORP. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL Normalized: mynx control |
Device | CORDIS US CORP. | $13.00 | 1 | 2025 |
Source payment records
|
|||||
| Technical Education MRI Normalized: technical education mri |
Device | Philips North America LLC | $12.73 | 1 | 2025 |
Source payment records
|
|||||
| AngioSculpt PV Normalized: angiosculpt pv |
Device | Philips North America LLC | $12.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
63 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 862 | 339 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 731 | 315 |
| Pantoprazole Sodium | Pantoprazole Sodium | 702 | 268 |
| Metoprolol Succinate | Metoprolol Succinate | 369 | 157 |
| Valsartan | Valsartan | 141 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 123 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 118 | 90 |
| Xarelto | Rivaroxaban | 114 | 44 |
| Potassium Chloride | Potassium Chloride | 110 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 104 | 48 |
| Nebivolol Hcl | Nebivolol Hcl | 100 | 49 |
| Lisinopril | Lisinopril | 94 | 41 |
| Doxycycline Hyclate | Doxycycline Hyclate | 82 | 72 |
| Torsemide | Torsemide | 70 | 29 |
| Entresto | Sacubitril/Valsartan | 63 | 22 |
| Furosemide | Furosemide | 59 | 23 |
| Ranolazine Er | Ranolazine | 51 | 24 |
| Eliquis | Apixaban | 48 | 18 |
| Gabapentin | Gabapentin | 40 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 37 | 24 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 35 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 18 |
| Farxiga | Dapagliflozin Propanediol | 34 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 14 |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Prednisone | Prednisone | 28 | 15 |
| Famotidine | Famotidine | 27 | 15 |
| Levothyroxine Sodium | Levothyroxine Sodium | 27 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 18 |
| Methylprednisolone | Methylprednisolone | 19 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 11 |
| Brilinta | Ticagrelor | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Pacerone | Amiodarone Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Metformin Hcl | Metformin Hcl | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,238.14 · 150 records | Cardio Flow, Inc. | ALPHAVAC, AURYON LASER SYSTEM 100-120 VAC, AngioSculpt PV, CAPVAXIVE, DIAMONDBACK PERIPHERAL, ELUVIA, ESPRIT, EVKEEZA, Encore, FFRANGIO, FREESTYLE LIBRE 3, GORE VIABAHN VBX Balloon Expandable Endo, General - CRM_CRM, General - Therapies, HI-TORQUE COMMAND, HT Bilevel Pro Core, INCEPTIV, IV Other, LEQVIO, LUTONIX Drug Coated Balloon, LYMPHA PRESS OPTIMAL PLUS(US) BT, Laser Parts Other, LifeStream, LifeVest, MYNX CONTROL, MYNX CONTROL VENOUS, MYNXGRIP, Other Rental, Ozempic, PCD-51 731A (US) - White, PCD-52 737A (US) White, PERCLOSE PROSTYLE, PRECISE PRO RX, Pounce Thrombectomy, Pounce Thrombectomy System, Pounce Venous Thrombectomy System, RADIAL 360, RotarexS 6 F x 135 cm, SABER, SUPERA, Serrantor, Specialty Tempus IC Monitor, Sublime 014 Rx PTA Balloon Dilatation Catheter, Sublime Microcatheter, 018, 200cm, Straight, TURBOHAWK, Technical Education MRI, VENACURE 1470 PRO, VERQUVO, Venovo, WATCHMAN, WATCHMAN FLX, Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error